Evidence map›Paper›PMID 39590113›Full record

ArticleCurrent oncology (Toronto, Ont.)2024

Prognostic Factors for Patients with Small-Cell Lung Cancer Treated with Chemoimmunotherapy: A Retrospective Multicenter Study.

Takashi Hatori, Takeshi Numata, Toshihiro Shiozawa, Manato Taguchi, Hirofumi Sakurai, Tomohiro Tamura, Jun Kanazawa, Hiroaki Tachi, Kyoko Kondo, Kunihiko Miyazaki and 4 more

Abstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Current oncology (Toronto, Ont.), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Takashi HatoriDepartment of Respiratory Medicine, Faculty of Medicine, University of Tsukuba, Tsukuba 305-8575, Ibaraki, Japan.
Takeshi NumataDivisions of Respiratory Medicine, Mito Medical Center, Ibarakimachi 311-3193, Ibaraki, Japan.
Toshihiro ShiozawaDepartment of Respiratory Medicine, Faculty of Medicine, University of Tsukuba, Tsukuba 305-8575, Ibaraki, Japan.ORCID 0000-0002-5869-8494
Manato TaguchiDivision of Respiratory Medicine, Moriya Daiichi General Hospital, Moriya 302-0102, Ibaraki, Japan.
Hirofumi SakuraiDivision of Respiratory Medicine, Ibaraki Seinan Medical Center Hospital, Sakai 306-0433, Ibaraki, Japan.
Tomohiro TamuraRespiratory Center, Ibaraki Prefectural Central Hospital, Kasama 310-8555, Ibaraki, Japan.
Jun KanazawaDepartment of Respiratory Medicine, National Hospital Organization, Ibaraki Higashi National Hospital, Tokai-Village 319-1113, Ibaraki, Japan.
Hiroaki TachiDivisions of Respiratory Medicine, Hitachi General Hospital, Hitachi 317-0077, Ibaraki, Japan.
Kyoko KondoDivision of Respiratory Medicine, Ryugasaki Saiseikai Hospital, Ryugasaki 301-0854, Ibaraki, Japan.
Kunihiko MiyazakiDivision of Respiratory Medicine, Ryugasaki Saiseikai Hospital, Ryugasaki 301-0854, Ibaraki, Japan.
Norihiro KikuchiDivision of Respiratory Medicine, Kasumigaura Medical Center, Tsuchiura 300-8585, Ibaraki, Japan.
Koichi KurishimaDivision of Respiratory Medicine, Tsukuba Medical Center Hospital, Tsukuba 305-8558, Ibaraki, Japan.
Hiroaki SatohDivision of Respiratory Medicine, Mito Kyodo General Hospital, Mito 310-0015, Ibaraki, Japan.
Nobuyuki HizawaDepartment of Respiratory Medicine, Faculty of Medicine, University of Tsukuba, Tsukuba 305-8575, Ibaraki, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThis study aimed to investigate prognostic factors for predicting the survival of patients with extensive-disease-stage small-cell lung cancer treated with chemoimmunotherapy.

methodsPatients were classified according to overall survival (OS): favorable corresponded to an OS ≥ 24 months, moderate corresponded to an OS of 6-24 months, and poor corresponded to an OS < 6 months. Multivariate Cox regression analyses were used to evaluate prognostic factors.

resultsOf 130 patients, the proportions of performance status decline and liver metastasis were significantly higher in the poor-prognosis group. With regard to the laboratory findings, neutrophil/lymphocyte ratios and albumin levels differed significantly among the groups. Multivariate analysis showed that the independent prognostic factors for OS were liver metastasis and decreased albumin levels (<3.5 mg/dL). After classifying the patients into three groups according to the quantities of these prognostic factors, the OS differed significantly among the groups (18.3 vs. 13.5 vs. 3.8 months;

conclusionLiver metastasis and decreased albumin levels are independent unfavorable prognostic factors. Patients with both prognostic factors showed unfavorable OS; however, patients without these factors may have a favorable prognosis but be at greater risk of irAEs.

Indexed as

ImmunotherapyLung NeoplasmsSmall Cell Lung CarcinomaAdultAgedAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsFemaleHumansMaleMiddle AgedPrognosisRetrospective Studiesalbuminimmune-related adverse eventimmunotherapyliver metastasisprognosissmall cell lung cancer

Identifiers

PMID39590113
PMCPMC11592429

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.